Medicare drug pricing reform is no longer just a policy issue for Washington. It is becoming a practical business issue for specialty practices.
In January 2026, the Centers for Medicare & Medicaid Services (CMS) selected 15 additional drugs for Medicare negotiation for 2028, including the first drugs payable under Part B. For buy-and-bill infusion providers, that shifts the conversation from policy awareness to early operational planning.
What to Know
- The first negotiated prices that can directly affect selected Part B drugs are scheduled to take effect on January 1, 2028.
- The 2028 selected list includes several products relevant to physician-administered and infusion settings, including Orencia, Entyvio, Xolair, Botox, and Cimzia.
- CMS has clarified that units sold at the Maximum Fair Price (MFP) will be included in average sales price (ASP) calculations, and the Medicare Part B Drug Payment Limit File will display an MFP-based payment limit when applicable.
- Even before negotiated prices take effect, practices should be evaluating exposure, reimbursement assumptions, payer contracts, and access workflows because the planning window is already open.
Why Medicare Drug Negotiation Matters for Buy-and-Bill Infusion Practices
Buy-and-bill economics depend on a careful balance between acquisition cost, reimbursement, and the operational costs of storage, handling, administration, and revenue cycle management.
Currently, most separately payable Part B drugs are reimbursed based on ASP. As the Medicare Drug Price Negotiation Program begins to influence payment benchmarks for selected products, practices may face tighter spreads and greater pressure on margins, cash flow, and forecasting.
For buy-and-bill infusion practices in particular, this is not just about headline drug prices. It is about whether reimbursement continues to support the real cost of delivering treatment in community settings. Even modest compression of reimbursement can be meaningful for practices with concentrated exposure to high-cost biologics. That makes early financial modeling essential.
What Is Changing in Medicare Part B Drug Pricing for Infusion Practices
The Medicare Drug Price Negotiation Program is still targeted, not universal. CMS selects high-spend single-source drugs and biologics that meet statutory criteria, including the absence of marketed generic or biosimilar competition. But the inclusion of Part B drugs in the 2028 cycle matters because it brings physician-administered therapies directly into the negotiation framework.
Just as important, CMS has made clear that MFP units will be reflected in ASP calculations. That means Medicare negotiation may influence future reimbursement benchmarks beyond the immediate negotiated payment period. For practices that also manage payer contracts or reimbursement methodologies tied to ASP, this creates a broader strategic issue, not simply a Medicare fee-for-service issue.
Where Broader Pricing Pressure Shows Up
Infusion practices should also recognize that Medicare drug negotiation is only one part of a broader pricing environment.
The Inflation Reduction Act has already introduced inflation rebate policies for certain Part B drugs, reducing beneficiaries’ coinsurance when drug prices rise faster than inflation. That does not operate the same way as negotiated pricing, but it signals the same broader reality: federal pricing pressure is becoming a more durable part of the reimbursement landscape.
For practice leaders, the takeaway is clear. Waiting until 2028 to assess the impact is too late. The operational implications are already visible in strategic planning, budgeting, and payer discussions.
How Buy-and-Bill Infusion Practice Leaders Should Prepare for Medicare Drug Negotiation
Medicare drug negotiation may not affect every infused therapy immediately, but it is already changing the strategic environment for buy-and-bill providers. As a result, practice leaders should use this window to evaluate financial exposure, review reimbursement assumptions, and strengthen operational readiness before added pricing pressure begins to reshape margins and access.
Map Exposure
Identify which infused or physician-administered therapies in your portfolio are already selected, potentially negotiation-eligible, or vulnerable to future pricing pressure. Segment by HCPCS, payer mix, and site of care.
Model Financial Impact
Stress-test gross margin, working capital needs, and reimbursement assumptions under lower payment scenarios for high-exposure drugs to identify where margin is durable and where it is vulnerable.
Review Contracts and Procurement Strategy
Assess payer contracts, GPO strategy, and vendor agreements for ASP-linked terms that may become less favorable as benchmarks evolve. This is the time to identify vulnerabilities before pressure intensifies.
Protect Patient Access
Reinforce biosimilar readiness, prior authorization workflows, and patient financial communication. In a tighter reimbursement environment, strong access operations become even more important to care continuity.
FAQ
When will Medicare drug negotiation directly affect Part B infusion drugs?
For the Part B drugs selected in January 2026, negotiated prices are scheduled to take effect on January 1, 2028.
Will every infusion drug be subject to Medicare negotiation?
No. The program applies only to a limited number of high-spend negotiation-eligible drugs that meet statutory requirements.
Which selected drugs are especially relevant to physician-administered settings?
Among the 2028 selected drugs, products with notable Part B relevance include Orencia, Entyvio, Xolair, Botox, and Cimzia.
What Should Buy-and-Bill Infusion Practices Do First to Prepare for Medicare Drug Negotiation?
Start with exposure mapping and reimbursement modeling now. Practices that treat Medicare negotiation as a contract, margin, and access management issue today will be better positioned to adapt later.
